Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –– Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically
Zenas tested a new medicine called obexelimab on sick patients. The results showed the medicine kept working well over time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.